Scientific Highlights: Research Division "Photon Science"

Guizar-Sicairos ICO prize ceremony

Dr. Manuel Guizar-Sicairos is awarded ICO prize

Dr. Manuel Guizar-Sicairos, beamline scientist at the cSAXS beamline, is the 2019 recipient of the International Commission for Optics (ICO) Prize. The distinction was awarded in the EOSAM conference in Rome.

nanobodies

Nanobodies against SARS-CoV-2

In a study published in EMBO Journal, researchers at the Max Planck Institute for Biophysical Chemistry, Göttingen, Germany, developed nanobodies that efficiently block the coronavirus SARS-CoV-2 and its variants. The high resolution structural characterization was performed at the X10SA crystallography beamline at the Swiss Light Source.

toc fig nno

Creating novel quantum phases via the heterostructure engineering

Within this synergetic collaboration, PSI scientists have investigated the correlation between magnetic and electronic ordering in NdNiO3 by tuning its properties through proximity to a ferromagnetic manganite layer. The main outcome is that the stray magnetic field from the manganite layer causes a novel ferromagnetic-metallic (FM-M) phase in NNO. This work demonstrates the utilization of heterostructure engineering for creating novel quantum phases.

synchrotronmovies

Synchrotron movies

Prof Philip Willmott, the author of the book 'Introduction to Synchrotron Radiation: techniques and applications' (second edition, John Wiley & Sons, Chichester, 2019. ISBN: 9781119280392), makes the scripts for the simulations and animations available to the public.

SARS-CoV-2_orf9b

Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions

In a study published in Nature Communications, researchers at the NHC Key Laboratory of Systems Biology of Pathogens in Beijing, China, in collaboration with the Paul Scherrer Institut characterize the interactions of SARS-CoV-2 orf9b and human TOM70 biochemically, and they determine the 2.2 Å crystal structure of the TOM70 cytosolic domain with a bound SARS-CoV-2 orf9b peptide.